Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scan.

For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scans within one week.

0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

Gadobutrol

H WM van Laarhoven, M.D., Ph.D.

Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at an early stage. Preferably, these markers could be determined non-invasively and provide insight into the biology of pancreatic cancer. Several MR techniques can serve for this purpose. However, optimalisation of these techniques is needed and their reproducibility should be assessed.

Background of the study:

Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at an early stage. Preferably, these markers could be determined non-invasively and provide insight into the biology of pancreatic cancer. Several MR techniques can serve for this purpose. However, optimalisation of these techniques is needed and their reproducibility should be assessed.

Objective of the study:

To optimize DCE-MRI, T2\* MRI and DWI in pancreatic cancer at 3T and investigate its reproducibility.

Study design:

In the first part of the study, patients with pancreatic cancer will undergo an MR measurement protocol once at 3T, to optimize MR techniques (DCE-MRI, T2\* MRI and DWI). In the second part of the study, to assess reproducibility patients will undergo the MR measurement protocol twice within one week before start of any treatment.

Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study

To assess reproducibility, 15 patients will undergo the MR measurement protocol twice within one week before start of any treatment.

Reproducibility of; DWI: mean ADC of the whole tumor. DCE: mean Ktrans of the whole tumor. T2\*: average value of the whole tumor.

In those patients for whom tumor tissue is available which has not been treated with radiation or chemotherapy, DCE-MRI, T2\* MRI and DWI will be compared with immunohistochemical markers of vascularity, hypoxia and stroma (e.g. CD-31, HIF1-alfa, CA9, GLUT1, PAI-1, VEGF, anti-SMA).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study	NCT01995240	Pancreatic Canc...	Gadobutrol	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study	NCT01995240	Pancreatic Canc...	Gadobutrol	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study	NCT01995240	Pancreatic Canc...	Gadobutrol	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Spots Global Cancer Trial Database for reproducibility